Stockscreener 앱 받기
1.14
0.87%
-0.01
시간 외 거래:
1.07
-0.07
-6.14%
전일 마감가:
$1.15
열려 있는:
$1.16
하루 거래량:
39,565
Relative Volume:
0.52
시가총액:
$9.94M
수익:
$6.74M
순이익/손실:
$-14.74M
주가수익비율:
-0.5069
EPS:
-2.2491
순현금흐름:
$-18.31M
1주 성능:
+3.64%
1개월 성능:
+2.70%
6개월 성능:
-13.64%
1년 성능:
-35.23%
1일 변동 폭
$1.10
$1.17
1주일 범위
$1.08
$1.21
52주 변동 폭
$0.93
$2.42
Evogene Ltd Stock (EVGN) Company Profile
EVGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
1.14 | 10.02M | 6.74M | -14.74M | -18.31M | -2.2491 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-10-08 | 개시 | ROTH Capital | Buy |
| 2021-07-29 | 개시 | Aegis Capital | Buy |
| 2020-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2013-12-16 | 개시 | Oppenheimer | Outperform |
Evogene Ltd 주식(EVGN)의 최신 뉴스
How Evogene Ltd. stock compares to industry benchmarksInterest Rate Changes & Affordable Portfolio Growth - ulpravda.ru
Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders - PR Newswire
Evogene (NASDAQ:EVGN) Stock Passes Below Fifty Day Moving Average – Time to Sell? - Defense World
Panic Selling: Will Evogene Ltd stock remain a Wall Street favorite2025 Price Targets & Low Drawdown Trading Strategies - moha.gov.vn
Evogene Appoints Dr. Olga Nissan as Vice President of Business Development to Drive AI-Driven Growth - The Globe and Mail
Evogene appoints Dr. Olga Nissan as VP of business development By Investing.com - Investing.com Nigeria
Evogene appoints Nissan as VP of Business Development - TipRanks
Evogene appoints Dr. Olga Nissan as VP of business development - Investing.com
Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development - Barchart.com
Will Evogene Ltd. stock remain a Wall Street favoriteQuarterly Growth Report & Smart Allocation Stock Reports - Bölüm Sonu Canavarı
Is Evogene Ltd. stock resilient to inflationJuly 2025 Setups & Free Daily Entry Point Trade Alerts - Улправда
Will Evogene Ltd. stock benefit from upcoming earnings reportsJuly 2025 Drop Watch & AI Based Trade Execution Alerts - DonanımHaber
Can Evogene Ltd. stock sustain market leadershipWeekly Gains Report & Safe Capital Investment Plans - DonanımHaber
Can Evogene Ltd. stock sustain free cash flow growth2025 Price Momentum & Entry and Exit Point Strategies - DonanımHaber
Should I hold or sell Evogene Ltd. stock in 20252025 Volume Leaders & Technical Buy Zone Confirmation - Улправда
Why Evogene Ltd. stock appeals to dividend seekersJuly 2025 Technicals & Weekly High Conviction Ideas - DonanımHaber
Is Evogene Ltd. stock attractive for growth ETFsBreakout Watch & Intraday High Probability Setup Alerts - Улправда
Will Evogene Ltd. stock keep outperforming rivalsWeekly Stock Recap & Growth Focused Investment Plans - Улправда
Reviewing Vera Therapeutics (NASDAQ:VERA) & Evogene (NASDAQ:EVGN) - Defense World
Will Introduced Innovation Sustain VLS Finance Limiteds GrowthInterest Rate Changes & Superior Trading Strategies - earlytimes.in
Investment Recap: Is Evogene Ltd stock a smart buy before Fed meetingTrade Entry Report & Free Growth Oriented Trading Recommendations - BỘ NỘI VỤ
Evogene (NASDAQ:EVGN) Stock Crosses Below Two Hundred Day Moving Average – Time to Sell? - Defense World
How AI Is Breaking Down the Bottlenecks in Small Molecule Drug Discovery - Unite.AI
Evogene (EVGN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session - Sahm
Evogene (NASDAQ:EVGN) Share Price Passes Below Two Hundred Day Moving Average – What’s Next? - Defense World
Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL (PR Newswire) - Aktiellt
Evogene shares climb 5% as cost reductions help deliver earnings beat - MSN
Evogene Ltd. Reports Strategic Shift and Financial Results - MSN
Evogene Ltd. Earnings Call: Strategic Shifts and Optimism - The Globe and Mail
Is Evogene Ltd. stock cheap compared to fundamentals - newser.com
Evogene Ltd. (NASDAQ:EVGN) Q3 2025 Earnings Call Transcript - Insider Monkey
Can Evogene Ltd. stock hit record highs again2025 Sector Review & Accurate Entry/Exit Alerts - newser.com
Is Evogene Ltd. stock oversold or undervalued2025 Key Highlights & Free Real-Time Volume Trigger Notifications - newser.com
Evogene: Q3 Earnings Snapshot - Stamford Advocate
Evogene earnings beat by $0.12, revenue fell short of estimates - Investing.com Australia
Evogene Q3 2025 Earnings Call Transcript - MarketBeat
Earnings Call Summary | Evogene(EVGN.US) Q3 2025 Earnings Conference - 富途牛牛
Earnings call transcript: Evogene reports Q3 2025 earnings beat amid restructuring - Investing.com India
Evogene shares rise 5% as cost-cutting measures drive earnings beat - Investing.com Nigeria
Evogene Reports Third Quarter 2025 Financial Results - The AI Journal
Evogene Reports Q3 2025 Financial Results Amid Strategic Shift - TipRanks
Israeli biotech firm Evogene's Q3 revenue misses estimates due to reduced seed sales - TradingView
Evogene shares rise 5% as cost-cutting measures drive earnings beat By Investing.com - Investing.com South Africa
Evogene : Q3 2025 Consolidated Financial Statements - MarketScreener
Evogene Ltd (EVGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
28.63%
자본화:
|
볼륨(24시간):